Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.
Press releases published on April 30, 2025
Rhinoplasty, Facelift, Eyelid Surgery: Philadelphia Facial Plastic Surgeons Discuss the Most Popular Options
EIN Presswire
·
April 30, 2025
Board-certified facial plastic surgeons Jonathan Pontell, MD and Dr. Catherine Weng explain key details about the most sought-after facial surgery procedures. PHILADELPHIA, PA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- With an overall steady …
HMP Global Expands Dermatology Portfolio with Acquisition of Masterclasses in Dermatology
EIN Presswire
·
April 30, 2025
Renowned brands to extend reach and deepen practical education in clinical care. MALVERN, PA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- HMP Global, a leading omnichannel healthcare company delivering education, events, and market insights to …
Congratulations to Martha Selmon of USC, the 2025 CAHME/Nancy Rosenthal Scholarship Recipient
EIN Presswire
·
April 30, 2025
SPRING HOUSE , PA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- Martha Selmon, a Master of Healthcare Administration (MHA) Candidate at the University of South Carolina, has been named the 2025 recipient of the CAHME/Nancy Rosenthal Scholarship. …
Congratulations to Merry Jiang of JHU, the 2025 CAHME/Olin Oedekoven Scholarship Recipient for Most Improved Student
EIN Presswire
·
April 30, 2025
SPRING HOUSE , PA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- Merry Jiang, a Master of Healthcare Administration (MHA) Candidate at Johns Hopkins University, has been named the 2025 recipient of the CAHME/Olin Oedekoven Scholarship for Most …
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
GlobeNewswire
·
April 30, 2025
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read Neurocrine’s announcement (link) Tokyo, Japan …
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
GlobeNewswire
·
April 30, 2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix …
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
GlobeNewswire
·
April 30, 2025
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan …
UPDATE – The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
GlobeNewswire
·
April 30, 2025
STUDIO CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’Dwyer, who lived with myeloma for 18 …
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire
·
April 30, 2025
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure to file …
AdCare Hospital Names New Executive Director to Tackle Growing Addiction Crisis Across Massachusetts
GlobeNewswire
·
April 30, 2025
WORCESTER, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- As Massachusetts continues to see waves of preventable deaths from the opioid overdose epidemic, AdCare Hospital, a longstanding provider of addiction treatment services in Worcester, MA, has named Laura …
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
GlobeNewswire
·
April 30, 2025
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery …
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
April 30, 2025
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today …
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
GlobeNewswire
·
April 30, 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye …
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
GlobeNewswire
·
April 30, 2025
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in …
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 30, 2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
Best CBD Gummies of 2025: Cornbread Hemp CBD Products Help with Sleep, Pain, and Stress Relief
GlobeNewswire
·
April 30, 2025
Louisville, KY, April 30, 2025 (GLOBE NEWSWIRE) -- In a market saturated with cannabidiol (CBD) products, one company continues to lead with quality, transparency, and innovation. Cornbread Hemp has officially been named the provider of the Best CBD …
CooperCompanies Appoints Barbara Carbone to Board of Directors
GlobeNewswire
·
April 30, 2025
SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. …
Teladoc Health Reports First Quarter 2025 Results
GlobeNewswire
·
April 30, 2025
PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and …
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
GlobeNewswire
·
April 30, 2025
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, financial, and operational updates for …
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
GlobeNewswire
·
April 30, 2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial …